Aflibercept - Regeneron Pharmaceuticals/Bayer/Sanofi

Drug Profile

Aflibercept - Regeneron Pharmaceuticals/Bayer/Sanofi

Alternative Names: AVE-0005; BAY-865321; Eylea; Eylia; Vascular endothelial growth factor Trap; Vascular endothelial growth factor Trap-R1R2; VEGF Trap (R1R2); VEGF Trap-Eye; Zaltrap; Ziv-aflibercept

Latest Information Update: 06 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Developer Bayer HealthCare Pharmaceuticals; Bayer Yakuhin; Centre Oscar Lambret; GERCOR; Guys Hospital; Hellenic Cooperative Oncology Group; Moorfields Eye Hospital; National Cancer Institute (USA); Regeneron Pharmaceuticals; Sanofi; sanofi-aventis; University of Ulm
  • Class Antineoplastics; Eye disorder therapies; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Branch retinal vein occlusion; Central retinal vein occlusion; Choroidal neovascularisation; Colorectal cancer; Diabetic macular oedema; Wet age-related macular degeneration
  • Registered Diabetic retinopathy
  • Phase III Glaucoma
  • Phase II Central serous chorioretinopathy
  • No development reported Malignant ascites; Non-Hodgkin's lymphoma; Ovarian cancer; Solid tumours
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Combination therapy, First-line therapy) in France (SC)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma(Second-line therapy or greater) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy) in Japan (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top